- Download 69
- File Size 0.00 KB
- File Count 1
- Create Date July 9, 2020
- Last Updated September 30, 2022
China Mandatory Period Risk Evaluation Report and the latest PMS Requirements in NMPA and FDA
Did you know China, the second-largest medical device and in vitro diagnostic (IVD) industry market globally, is the only market with a 20 percent annual growth rate year after year?
Are you up to speed on the hundreds of new regulations introduced by China’s National Medical Products Administration (NMPA) — formally known as the China Food and Drug Administration?
What are the strategic factors to consider during the reform before your submission?